Zoetis Inc. (ZTS) Operating Cash Flow CAGR:N/A(TTM)
The operating cash flow cagr for Zoetis Inc. (ZTS) is N/A over the latest trailing 12-month period. Operating cash flow CAGR uses precomputed cash-flow statement history (cash from operations, before capital expenditures).
The operating cash flow cagr for Zoetis Inc. (ZTS) stock is N/A over the past 12 months. The 3 year average growth rate is 8.09% and the 5 year cagr is 5.12%. Operating cash flow CAGR measures the compound annual growth rate of the cash Zoetis Inc. generates from its core business operations, before capital expenditures, computed from rolling-twelve-month cash-flow statement history. The 1-year (TTM) figure is omitted: a one-year rate off a single quarter's base is volatile; the multi-year figures are the reliable read.
ZTS Operating Cash Flow CAGR Chart
Zoetis Inc. (ZTS)
ZTS Operating Cash Flow CAGR History
| Year | Start OCF | End OCF | Change | % Change | CAGR |
|---|---|---|---|---|---|
| 2025 | $2.95B | $2.90B | $-49.00M | -1.66% | -1.66% |
| 2024 | $2.35B | $2.95B | +$600.00M | +25.50% | +25.50% |
| 2023 | $1.91B | $2.35B | +$441.00M | +23.06% | +23.06% |
| 2022 | $2.21B | $1.91B | $-301.00M | -13.60% | -13.60% |
| 2021 | $2.13B | $2.21B | +$87.00M | +4.09% | +4.09% |
| 2020 | $1.79B | $2.13B | +$331.00M | +18.44% | +18.44% |
| 2019 | $1.79B | $1.79B | +$5.00M | +0.28% | +0.28% |
| 2018 | $1.35B | $1.79B | +$444.00M | +32.99% | +32.99% |
| 2017 | $713.00M | $1.35B | +$633.00M | +88.78% | +88.78% |
| 2016 | $664.00M | $713.00M | +$49.00M | +7.38% | +7.38% |
| 2015 | $626.00M | $664.00M | +$38.00M | +6.07% | +6.07% |
| 2014 | $681.00M | $626.00M | $-55.00M | -8.08% | -8.08% |
| 2013 | $454.00M | $681.00M | +$227.00M | +50.00% | +50.00% |
| 2012 | $497.00M | $454.00M | $-43.00M | -8.65% | -8.65% |
| 2011 | $254.00M | $497.00M | +$243.00M | +95.67% | +95.67% |
| 2010 | $98.00M | $254.00M | +$156.00M | +159.18% | +159.18% |
About Zoetis Inc.
Zoetis Inc. stands as a global leader in animal health, focusing on the research, development, manufacturing, and commercialization of veterinary pharmaceuticals, vaccines, and diagnostic tools. Its comprehensive portfolio serves a broad spectrum of species, encompassing both livestock, including cattle, swine, poultry, fish, and sheep, and beloved companion animals such as dogs, cats, and horses. Among its pharmaceutical offerings are various therapeutic agents. This includes vaccines, vital for preventing respiratory, gastrointestinal, and reproductive diseases by stimulating a targeted immune response; anti-infectives that combat or inhibit the proliferation of bacterial, fungal, or protozoal pathogens; and parasiticides aimed at eradicating both internal and external pests such as fleas, ticks, and various worms. Additional pharmaceuticals address areas such as pain management and sedation, anti-emesis, reproductive health, and oncology. The portfolio also features dermatological solutions for allergic skin conditions and atopic dermatitis, alongside medicated feed additives specifically designed for livestock. Beyond therapeutics, Zoetis offers an extensive array of diagnostic solutions. These include portable analysis systems for blood and urine, point-of-care testing devices, specialized instruments and reagents, rapid immunoassay kits, comprehensive reference laboratory services, and blood glucose monitoring equipment. Further extending its reach, the company provides supplementary offerings such as nutritional products, agribusiness support services, biodevices, genetic testing, and innovations in precision animal health. Zoetis distributes its diverse product portfolio to a broad customer base, including veterinary professionals, livestock producers, and retail channels. This distribution occurs directly via its sales representatives and technical specialists, as well as through partnerships with third-party veterinary distributors. Established in 1952, the company maintains its corporate headquarters in Parsippany, New Jersey.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Kristin C. Peck